Civetta Therapeutics, LLC

Civetta Therapeutics, LLC is a biotechnology company focused on the discovery and development of innovative cancer therapies through the use of proprietary drug discovery platforms and approach. Founded in 2019 and headquartered in Cambridge, US, Civetta Therapeutics, LLC specializes in cancer therapeutics. The company has completed one significant investment deal. In December 2019, Civetta raised USD 53 mn in Series A funding, marking its first round of financing.

The founder, William Sellers, is known for his previous contributions to cancer research and development, further establishing Civetta’s expertise in the field. Civetta Therapeutics develops innovative therapeutic solutions targeting cancer treatment. The company utilizes proprietary platforms to identify and validate novel drug candidates aimed at addressing unmet medical needs in oncology. Their research focuses on leveraging cutting-edge technologies to develop treatments that enhance patient outcomes in cancer care.

Civetta Therapeutics operates on a funding-based revenue model, relying primarily on investment rounds to support its research and development initiatives. The USD 53 mn raised from its latest Series A funding will be utilized to advance its pipeline of cancer therapies, focusing on further development and clinical testing of its drug candidates. Civetta Therapeutics plans to leverage the recent USD 53 mn Series A funding to expedite the development of its cancer therapies. The company is focused on launching new drug candidates in the oncology space within the next few years.

Additionally, they aim to expand their market presence in North America and Europe, targeting strategic partnerships to enhance their reach and impact in the global cancer therapeutics market.